- Only 20% of clinical trials for cell and gene therapy approvals reported identical data to both the U.S. FDA and the EMA.
- Variability in trial data reporting between regulatory agencies was documented, highlighting the need for regulatory harmonization.
- Sample size discrepancies and differing efficacy outcome values were observed across regulatory submissions.
- The study was limited by the absence of data on sponsor interactions with regulatory agencies.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
